Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ar-12. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 known ✓ | O15530 | 15/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ar-12 SCHEMBL30099806 | 1.00 | PDPK1 (1.00) | PDPK1MAPTPTGS2CA9TP53 | |
| SCHEMBL16195901 | 0.95 | PDPK1 (0.91) | PDPK1MAPTPTGS2TP53SMN1; SMN2 | |
| SCHEMBL29165677 | 0.93 | PDPK1 (0.87) | PDPK1MAPTPTGS2TP53SMN1; SMN2 | |
| SCHEMBL13608762 | 0.90 | PDPK1 (0.81) | PDPK1MAPTPTGS2CA9TP53 | |
| SCHEMBL978868 | 0.90 | PDPK1 (1.00) | PDPK1MAPTPTGS2TP53SMN1; SMN2 | |
| SCHEMBL981931 | 0.89 | PDPK1 (0.81) | PDPK1MAPTPTGS2CA9TP53 | |
| SCHEMBL16196304 | 0.89 | PDPK1 (0.80) | PDPK1MAPTPTGS2TP53SMN1; SMN2 | |
| SCHEMBL978943 | 0.88 | PDPK1 (0.85) | PDPK1MAPTPTGS2CA9TP53 | |
| SCHEMBL981939 | 0.87 | PDPK1 (0.77) | PDPK1MAPTTP53SMN1; SMN2THRB | |
| SCHEMBL19676864 | 0.86 | PDPK1 (0.76) | PDPK1MAPTPTGS2CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595256-B2 | Composition for organic electronic devices | MERCK PATENT GMBH (DE) | 2026-04-07 | — | — | US | claimed |
| EP-4453129-B1 | ELECTRONIC DEVICES | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-02-04 | — | — | EP | claimed |
| US-12522624-B2 | Electroluminescent material and device thereof | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2026-01-13 | — | — | US | claimed |
| EP-3727369-B1 | ANTI-FUNGAL AGENT FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN A SUBJECT WITH LOSS-OF FUNCTION MUTATION IN THE CX3CR1 GENE | UNIV CORNELL (US) | 2025-12-17 | — | — | EP | claimed |
| US-12441715-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2025-10-14 | — | — | US | claimed |
| US-20250268101-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2025-08-21 | — | — | US | claimed |
| WO-2025135555-A1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 솔루스첨단소재 주식회사 | 2025-06-26 | — | — | WO | claimed |
| CN-120025253-A | Compounds useful as active compounds in organic electronic devices | 默克专利有限公司 | 2025-05-23 | — | — | CN | claimed |
| EP-3728199-B1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2025-05-14 | — | — | EP | claimed |
| WO-2025080080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, CONTAINING PDK INHIBITOR AS ACTIVE INGREDIENT | 한양대학교 산학협력단 | 2025-04-17 | — | — | WO | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| WO-2020232445-A1 | MODULATORS OF PYRIMIDINE NUCLEOTIDE BIOSYNTHETIC PATHWAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-19 | — | — | WO | claimed |
| US-20190316095-A1 | METHODS FOR CREATING INTEGRATION-FREE, VIRUS-FREE, EXOGENOUS ONCOGENE-FREE IPS CELLS AND COMPOSITIONS FOR USE IN SUCH METHODS | Cellular Engineering Technologies, Inc. (US) | 2019-10-17 | — | — | US | claimed |
| US-9901569-B2 | Compositions and methods for inhibiting leishmania | OHIO STATE INNOVATION FOUNDATION (US) | 2018-02-27 | — | — | US | claimed |
| WO-2018026811-A2 | ANTIFUNGAL AGENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2018-02-08 | — | — | WO | claimed |
| WO-2018026812-A1 | ANTIVIRAL AGENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2018-02-08 | — | — | WO | claimed |
| WO-2016069854-A1 | ENHANCING THE ANTI-TUMOR, ANTI-VIRAL, AND ANTI-PROTOZOAN EFFECTS OF 2-AMINO-N-[4-[5-PHENANTHREN-2-YL-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL] PHENYL]ACETAMIDE (OSU-03012) AND OTHER PHARMACEUTICAL DRUGS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-05-06 | — | — | WO | claimed |
| WO-2014138881-A1 | DRUG DELIVERY SYSTEM | PATHEON, INC. (CA) | 2014-09-18 | — | — | WO | claimed |
| US-20140271872-A1 | DRUG DELIVERY SYSTEM | PATHEON INC. (CA) | 2014-09-18 | — | — | US | claimed |
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441715-B2 | Materials for organic electroluminescent devices | DDT, PNMT, ESD | PDPK1 4246/4885MAPT 175/4885PTGS2 2382/4885 |
| US-20250268101-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | NFE2L2, GPX1, ELP1 | PDPK1 3965/4885MAPT 1442/4885PTGS2 2552/4885 |
| US-20140271872-A1 | DRUG DELIVERY SYSTEM | LDLR, SLC10A1, SLC2A1 | PDPK1 3428/4885MAPT 2160/4885PTGS2 395/4885 |
| US-12595256-B2 | Composition for organic electronic devices | ABCB7, CYP1B1, AHR | PDPK1 4058/4885MAPT 2722/4885PTGS2 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.